$4.93
1.02% yesterday
NYSE, Sep 27, 10:17 pm CET
ISIN
US00445A1007
Symbol
SLRN
Sector
Industry

ACELYRIN Stock price

$4.93
-0.11 2.18% 1M
-1.82 26.96% 6M
-2.53 33.91% YTD
-4.87 49.69% 1Y
-13.07 72.61% 3Y
-13.07 72.61% 5Y
-13.07 72.61% 10Y
NYSE, Closing price Fri, Sep 27 2024
+0.05 1.02%
ISIN
US00445A1007
Symbol
SLRN
Sector
Industry

Key metrics

Market capitalization $487.06m
Enterprise Value $-147.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.68
P/B ratio (TTM) P/B ratio 0.86
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-375.33m
Free Cash Flow (TTM) Free Cash Flow $-217.49m
Cash position $635.24m
EPS (TTM) EPS $-3.06
P/E forward negative
Short interest 6.97%
Show more

Is ACELYRIN a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

ACELYRIN Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a ACELYRIN forecast:

4x Buy
57%
3x Hold
43%

Analyst Opinions

7 Analysts have issued a ACELYRIN forecast:

Buy
57%
Hold
43%

Financial data from ACELYRIN

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.26 0.26
-
-
-0.26 -0.26
-
-
- Selling and Administrative Expenses 82 82
-
-
- Research and Development Expense 292 292
-
-
-375 -375
-
-
- Depreciation and Amortization 0.26 0.26
-
-
EBIT (Operating Income) EBIT -375 -375
-
-
Net Profit -300 -300
-
-

In millions USD.

Don't miss a Thing! We will send you all news about ACELYRIN directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACELYRIN Stock News

Positive
Seeking Alpha
7 days ago
Acelyrin, Inc. shifts focus to developing lonigutamab for thyroid eye disease, aiming for phase 3 trials in Q1 2025, bypassing phase 2b/3 studies. Key catalysts include an end-of-phase 2 meeting and additional phase 2 data by the end of 2024, potentially boosting shareholder value. Lonigutamab offers a competitive edge with subcutaneous administration, higher potency, and lower adverse events c...
Neutral
GlobeNewsWire
9 days ago
LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive results from the company's global Phase 3 clinical trial of izokibep in moderate-to-severe hidradenitis suppurativa (HS) patients will be shared as a la...
Neutral
GlobeNewsWire
about one month ago
LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that members of its management team will participate in fireside chats and 1x1 meetings at the following investor conferences:
More ACELYRIN News

Company Profile

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Head office United States
CEO Mina Kim
Employees 130
Founded 2020
Website www.acelyrin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today